Host: |
Rabbit |
Applications: |
WB/ELISA |
Reactivity: |
Human/Mouse/Rat |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
PBS with 0.01% Thimerosal, 50% Glycerol, pH 7.3. |
Purification: |
Affinity purification |
Concentration: |
Lot specific |
Dilution Range: |
WB:1:500-1:2000ELISA:Recommended starting concentration is 1 Mu g/mL. Please optimize the concentration based on your specific assay requirements. |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
MAGEA4 |
Gene ID: |
4103 |
Uniprot ID: |
MAGA4_HUMAN |
Immunogen Region: |
28-317 |
Specificity: |
Recombinant fusion protein containing a sequence corresponding to amino acids 28-317 of human MAGEA4 (NP_002353.3). |
Immunogen Sequence: |
AQAPTTEEQEAAVSSSSPLV PGTLEEVPAAESAGPPQSPQ GASALPTTISFTCWRQPNEG SSSQEEEGPSTSPDAESLFR EALSNKVDELAHFLLRKYRA KELVTKAEMLERVIKNYKRC FPVIFGKASESLKMIFGIDV KEVDPASNTYTLVTCLGLSY DGLLGNNQIFPKTGLLIIVL GTIAMEGDSASEEEIWEELG VMGVYDGREHTVYGEPRKLL TQDWVQENYLEYRQVPGSN |
Tissue Specificity | Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes and placenta. |
Function | Regulates cell proliferation through the inhibition of cell cycle arrest at the G1 phase. Also negatively regulates p53-mediated apoptosis. |
Protein Name | Melanoma-Associated Antigen 4Cancer/Testis Antigen 1.4Ct1.4Mage-4 AntigenMage-41 AntigenMage-X2 Antigen |
Alternative Antibody Names | Anti-Melanoma-Associated Antigen 4 antibodyAnti-Cancer/Testis Antigen 1.4 antibodyAnti-Ct1.4 antibodyAnti-Mage-4 Antigen antibodyAnti-Mage-41 Antigen antibodyAnti-Mage-X2 Antigen antibodyAnti-MAGEA4 antibodyAnti-MAGE4 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance